Weekly shot may shield joints in hemophilia a patients
NCT ID NCT06752850
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a once-weekly medication (efanesoctocog alfa) can improve or prevent joint damage in 37 people with moderate or severe hemophilia A. Participants receive the drug for 12 months, and doctors use ultrasound and MRI to check joint health. The goal is to see if this treatment reduces swelling and lowers the risk of joint bleeds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sobi Investigational Site
Milan, Italy
-
Sobi Investigational Site
Naples, Italy
-
Sobi Investigational Site
Rozzano, Italy
-
Sobi Investigational Site
Oslo, Norway
-
Sobi Investigational Site
Barcelona, Spain
-
Sobi Investigational Site
Madrid, Spain
-
Sobi Investigational Site
Seville, Spain
-
Sobi Investigational Site
Valencia, Spain
-
Sobi Investigational Site
Gothenburg, Sweden
-
Sobi Investigational Site
Malmö, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a clotting boost make surgery safer for hemophilia patients?
- A facelift without the bruising? tranexamic acid put to the test.
- Deep gum cleaning may boost quality of life for hemophilia patients
- Can a video call replace the clinic for hemophilia pain relief?
- Experimental drug aims to reverse liver damage in rare triple condition
- Monthly shot could free kids with hemophilia from frequent infusions